NCT06139536 2024-03-13
Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients
Bio-Thera Solutions
Phase 1 Unknown
Clinical Trials
73 trialsNCT05103046 2024-03-12
First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors
1200 Pharma, LLC
Phase 1 Unknown
NCT05971862 2024-02-21
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SKI-G-801 in Patients With Advanced Solid Tumors
Oscotec Inc.
Phase 1 Unknown
NCT04934514 2024-02-20
Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors
SUNHO（China）BioPharmaceutical CO., Ltd.
Phase 1/2 Unknown
NCT05291182 2024-02-02
A Phase I Study of SY-4835 in Patients With Advanced Solid Tumors
Shouyao Holdings (Beijing) Co. LTD
Phase 1 Unknown
NCT05886868 2023-11-29
Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors
Shanghai Best-Link Bioscience, LLC
Phase 1 Unknown
NCT05101265 2023-11-27
Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment
PharmaMar
Phase 1 Unknown
NCT05681000 2023-11-09
Tolerability of Utidelone Capsule in Patients With Advanced Solid Tumors
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 1 Unknown
NCT05263180 2023-10-18
A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors.
Shanghai EpimAb Biotherapeutics Co., Ltd.
Phase 1 Unknown
NCT06054932 2023-09-26
Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors
Beijing Likang Life Science and Tech Co., Ltd.
Phase 1 Unknown
NCT06008366 2023-09-13
A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT06008379 2023-09-13
A Study of 7MW3711 in Subjects With Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT06006793 2023-09-01
A Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation
Shouyao Holdings (Beijing) Co. LTD
Phase 1 Unknown
NCT06019013 2023-08-31
A Study of QLF3108 in Participants With Advanced Solid Tumor
Qilu Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT05840835 2023-08-08
IMMINENT-01
Immix Biopharma, Inc.
Phase 1/2 Unknown
NCT05884801 2023-08-01
Phase I Study of QLS1103 in Subjects With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT05021367 2023-07-24
A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT05173805 2023-07-18
Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation
Shanghai YingLi Pharmaceutical Co. Ltd.
Phase 1/2 Unknown
NCT05950815 2023-07-18
A Study of PM1015 in Patients With Advanced Solid Tumors
Biotheus Inc.
Phase 1 Unknown
NCT05944185 2023-07-14
Phase I/II Study of αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid Tumors
Shanghai Cell Therapy Group Co.,Ltd
Phase 1/2 Unknown
NCT05794477 2023-06-02
A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2 Unknown
NCT05498519 2023-05-11
A First-in-Human, Phase 1 Study of SY-4798 in Patients With Advanced Solid Tumor
Shouyao Holdings (Beijing) Co. LTD
Phase 1 Unknown
NCT05837299 2023-05-01
A Study of IMC008 for Advanced Solid Tumors
Changhai Hospital
Phase 1 Unknown
NCT05829616 2023-04-25
A Phase I Study of QLS12004 in Patients With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT05824663 2023-04-21
A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors
Harbour BioMed US, Inc.
Phase 1 Unknown
NCT05805956 2023-04-10
IMM2902 in Patients With Advanced Solid Tumors Expressing HER2
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1/2 Unknown
NCT05801094 2023-04-06
A Phase I Study of QL1604 for Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT05434299 2023-03-16
A Study of TFX05-01 in Patients With Advanced Solid Tumors
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Phase 1/2 Unknown
NCT04947033 2023-03-14
A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors
I-Mab Biopharma US Limited
Phase 1 Unknown
NCT05276609 2023-02-15
ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors
Hansoh BioMedical R&D Company
Phase 1 Unknown
NCT05706207 2023-01-31
A Study of HB0030 Injection in Patients With Advanced Solid Tumors
Huabo Biopharm Co., Ltd.
Phase 1 Unknown
NCT05584709 2023-01-30
Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors
Sorrento Therapeutics, Inc.
Phase 1 Unknown
NCT05673538 2023-01-10
TT-00973-MS Tablets in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
Phase 1 Unknown
NCT05372120 2023-01-04
A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2 Unknown
NCT05644509 2022-12-09
Study on the Treatment of Advanced Malignant Solid Tumor With Revottack and PD-1 Inhibitor
The Affiliated Hospital of Xuzhou Medical University
Phase 1 Unknown
NCT05645315 2022-12-09
Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown
NCT04472858 2022-11-29
A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1 Unknown
NCT05205408 2022-11-29
A Study of Intratumoral Administration of Oncolytic Virus Injection (RT-01) in Patients With Advanced Solid Tumors
The First Affiliated Hospital of Bengbu Medical University
Phase 1 Unknown
NCT05461287 2022-11-10
Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT05522309 2022-10-04
FLIGHT
Etern BioPharma (Shanghai) Co., Ltd
Phase 1 Unknown
NCT05525559 2022-09-01
FIRST
Etern BioPharma (Shanghai) Co., Ltd
Phase 1 Unknown
NCT05515185 2022-08-25
B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors
The First People's Hospital of Lianyungang
Phase EARLY_PHASE1 Unknown
NCT05378178 2022-07-07
A Phaseâ… Study of HS-10381 in Patients With Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT05429398 2022-06-23
A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor
Shanghai YingLi Pharmaceutical Co. Ltd.
Phase 1 Unknown
NCT04058587 2022-06-06
A Phase I Trial of Simmitinib in Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Unknown
NCT05228119 2022-05-09
A Study of Oncolytic Virus Injection (RT-01) in Combination With PD-1 Inhibitor in Patients With Advanced Solid Tumors
The Affiliated Hospital of Xuzhou Medical University
Phase 1 Unknown
NCT05354843 2022-04-29
SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors
Etern BioPharma (Shanghai) Co., Ltd
Phase 1 Unknown
NCT05344742 2022-04-25
A Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Unknown
NCT05341570 2022-04-22
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668
Betta Pharmaceuticals Co., Ltd.
Phase 1 Unknown
NCT05202561 2022-03-23
A Study of RNA Tumor Vaccine in Patients With Advanced Solid Tumors
The First Affiliated Hospital of Bengbu Medical University
Phase 1 Unknown